Skip to main content
Erschienen in: BMC Medical Research Methodology 1/2007

Open Access 01.12.2007 | Research article

The impact of disease-related impairments on disability and health-related quality of life: a systematic review

verfasst von: Nadine Weisscher, Rob J de Haan, Marinus Vermeulen

Erschienen in: BMC Medical Research Methodology | Ausgabe 1/2007

Abstract

Background

To investigate the interchangeability of measures of disability and health-related quality of life (HRQL) by comparing their associations patterns with disease-related impairment measures in patients with a variety of conditions.

Methods

A systematic literature search of MEDLINE, EMBASE, Web of Science and a hand search of reference lists through January 2006. Studies were included if they reported associations patterns between impairment and disability and between impairment and HRQL. Correlation coefficients were transformed to Fisher's z effect size (ES(z)). Weighted averages were reported as pooled ES(z) with 95% confidence intervals (CI).

Results

The relationship between impairment and disability was stronger (pooled ES(z) = 0.69; 95% CI, 0.66 – 0.72) than between impairment and HRQL (pooled ES(z) = 0.38; 95% CI, 0.36 – 0.41). The physical component score (pooled ES(z) = 0.43; 95% CI, 0.39 – 0.47) and disease-specific HRQL (pooled ES(z) = 0.46; 95% CI, 0.40 – 0.51) were stronger associated with impairments than the mental component score (pooled ES(z) = 0.28; 95% CI, 0.20 – 0.36) and generic HRQL (pooled ES(z) = 0.36; 95% CI, 0.33 – 0.39).

Conclusion

This study shows measures of disability and different HRQL domains were not equally related to impairment. Patient's impairments are better reflected in disability measures, than in HRQL instruments. There are many outcomes of interest and precisely defining them and measuring them will improve assessing the impact of new interventions.
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1471-2288-7-24) contains supplementary material, which is available to authorized users.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

NW, RdH and MV initiated the project. NW and RdH screened, extracted and analysed the data. All authors participated in the discussion of the results, in the writing of the paper, and read and approved the final manuscript.

Background

Choosing an outcome measure for use in clinical research is a complex process. If the outcomes are chosen inappropriately, a study may provide unreliable results [1]. Frequently used outcomes measures are mortality rates, number of events (recurrent myocard infarction) or disease activity (lesion load on MRI).
Besides biological measures other levels of clinical measurement can be considered in clinical studies: impairments, disability and health-related quality of life (HRQL). Impairments are the direct organic manifestations of the disease such as consciousness and paresis [2, 3]. Disability can be defined as limitations in carrying out activities of daily living, such as self-care, mobility and activities inside or outside the home [2, 3]. HRQL refers to a broad spectrum of consequences of disease. Although this concept also includes elements of impairments and disabilities, it has a strong focus on patient's social functioning and perceived health status and well being [4, 5]. Hence, impairment measures are closely related to the patient's disorder, whereas the other outcome measures focus on the patient's level of functional health. Each subsequent level of clinical measurement is increasingly less disease-specific and more relevant to the patient.
Recently, patient-relevant outcomes in terms of disability and HRQL have become more important [6]. Although both functional outcomes reflect the consequences of diseases on personal level, they are conceptually different and not synonymous as is often thought by clinical researchers. Consequently, the decision to use one of these measures can have important implications for the interpretation of the study results. The objective of this systematic review is to investigate the interchangeability of measures of disability and HRQL by comparing their association patterns with disease-related impairment measures.

Methods

Data sources

We conducted a systematic literature search of MEDLINE from 1966 through January 2006, EMBASE from 1980 through January 2006 and Web of Science from 1988 through January 2006 to identify studies addressing the relation between outcome measures. A search strategy using Medical Subject Heading, text words and Publication Types Impairment or Body function (Publication date from 2001) or Body structure (Publication date from 2001) and Disability (Evaluation) or Activity or Disabled Persons or Activities of Daily Living and Health-related quality of life combined with Association or Evaluation Studies or Comparative Study or Validation Studies was used. Studies from English, German and French literature were included. The electronic search was supplemented by hand searching the investigators files, and retrieval of references cited in available literature. The search strategy was composed by one of the authors (NW) in consultation with a clinical librarian.

Study selection

A set of explicit criteria, composed by three investigators (NW, RdH, MV), were used for selection of the literature. Articles were included if they focused on methodological or metric aspects of patient-based outcomes (for example, methods of evaluating such measures, psychometric or clinimetric assessment of measures, comparative studies of measures).
Studies were included in which both the association between impairment and disability, and between impairment and HRQL were calculated by means of correlation coefficients or other association measures, regardless of the disease with the exception of psychiatric disorders. Hence, to improve the comparability between the correlation patterns between the different health concepts, only studies were included in which the three types of health outcomes were assessed in the same patient population. The measurement instruments were questionnaires or observation lists. When a multi-scale questionnaire focuses on more than one concept we only included the sub-scale for the health domain in question. In case of double publication we selected the first publication in time. Excluded were studies which valuated HRQL in terms of utilities [7] or composite scores of conceptual different measures.

Data extraction

All data were independently abstracted by two investigators (NW, RdH) through use of a list of the criteria composed by three investigators. After study selection, measures were categorized according the definitions of the WHO International Classification of Impairments, Disabilities, and Handicap version [2] and the revised International Classification of Functioning [3]. Outcome measures were classified into one of the following categories: impairment, disability, and HRQL. The latter was further categorized into generic HRQL, disease-specific HRQL, mental component of HRQL and physical component of HRQL. When there was doubt on the classification of the health domain a third reviewer (MV) was consulted.
A first draft synthesizing the data was produced by the first author of this review (NW) and extensively criticized by two other authors. The following information was abstracted: author, year of publication, sample size, disease, type of impairment and disability scales, distinction between generic or disease-specific and mental or physical HRQL, and the associations with impairment. Studies reporting repeated measures only baseline data was abstracted. Disagreements in abstracting were solved by discussion.

Statistical analysis

The correlations coefficients (r) published were converted using Fischer's variance stabilizing z transform (ES(z)) [8].
ES(z) = 1/2 loge [1+r/1-r]
were the asymptotic variance was:
v ES(z) = 1/n-3
Mean ES(z) were calculated for studies reporting multiple correlations between the concepts studied [9]. The ES(z) were combined using a fixed or random effects model, when appropriate. The weight for each study was inversely proportional to the square root of the number of patients included in the study. The methods for obtaining the pooled ES(z) and its 95% confidence interval (CI) are described in detail elsewhere [10]. We labeled the strength of the ES 0.20 as small, 0.50 as medium and 0.80 as large [11]. The pooled ES(z) were converted back to a correlation coefficient [12]:
r = tanh(ES(z))
in which we labeled the strength of the association; absolute values of r, 0.00–0.19 is regarded as very weak, 0.20–0.39 as weak, 0.40–0.59 as moderate, 0.60–0.79 as strong and 0.80–1.00 as very strong correlation [13]. The backward transformed correlation coefficients were also expressed in variance explained (r2). The square of the correlation coefficient tells us what proportion of the variance of one variable can be explained by the linear correlation with the other.
Statistical heterogeneity was measured using the Cochrane Q statistics; p ≤ 0.10 was considered representative of significant statistical heterogeneity. To establish the effect of heterogeneity between studies on meta-analysis conclusions, we performed several subgroup analyses: impairment in relation to generic or disease-specific HRQL and impairment versus the physical or mental aspects of HRQL.
We constructed normal quantile plots to assess whether the ES(z) estimates are (approximately) normal distributed and to search for publication bias [14]. With regard to the presence of publication bias we also used the Spearman's rho rank correlation method [12] to test the relationship between the standardized ES(z) and sample size (p < 0.05 indicates significant publication bias) and a fail-safe number approach. A fail-safe number is the number of non-significant, unpublished, or missing studies that would need to be added to the meta-analysis in order to change the results of the analysis. If this number is relative large to the number of observed studies, the observed results, even with some publication bias, can be treated as a reliable estimate of the true effect [15]. All analyses were performed in Meta-Win, version 2.0.

Results

Study characteristics

Our initial search yielded 434 potentially literature citations (Figure 1). Of these, 125 were excluded based on title (70 were investigating a psychiatric disorder, 44 were review articles, nine articles measured caregiver burden, one article reported data about a composite score and one reported HRQL in terms of utilities). Abstracts from 309 articles were retrieved and additional 188 articles were excluded (134 studies did not measure all three health domains, 49 did not report concrete associations between the health domains, three were investigating a psychiatric disorder, one reported data about a composite score and one reported HRQL in terms of utilities), leaving 121 articles for full review. Of these, 90 were excluded (44 did not report association patterns, 34 articles measured not all three domains, in five articles impairment measures were no scale score, four articles used composite scores, one reported utility based HRQL, one concerned a proxy measure and one a double publication).
A total of 31 studies, with an average sample size of 401 (range 38 – 6497) persons, were found to conform to our inclusion criteria [1646] (Table 1). Seven studies reported data on outcome measures in patients with arthritis, six on Multiple Sclerosis, three on Parkinson's disease, two on stroke, two on spinal cord injury, four on a variety of joint diseases (knee, patella, elbow, shoulder), one cervical dystonia, one diabetic neuropathy, one facial nerve paralysis, one AIDS, one chronic dysphonia, one chronic obstructive pulmonary disease, and one on psoriasis.
Table 1
Information on the 31 studies included in the analysis ordered on disease
References
N
Disease
Impairment
Disability
HRQL
     
Generic
Specific
Deyo, 1983 [22]
97
Arthritis
Morning stiffness Grip strength
SIP physical ARA
SIP total SIP psychosocial
 
Birrell, 1998 [19]
86
Arthritis
OSRA
HAQ
SF-36
 
Kvien, 1998 [29]
1030
Arthritis
VAS pain VAS fatigue
MHAQ
SF-36
AIMS2
Wolfe, 2000 [45]
1773
Arthritis
Global GI severity
HAQ
SF-36
 
Angst, 2004 [16]
43
Arthritis
cASES
pASES DASH
SF-36
 
Angst, 2005 [17]
79
Arthritis
cASES
pASES DASH
SF-36
 
Salaffi, 2005 [39]
244
Arthritis
WOMAC-Pain WOMAC-Stiffness
WOMAC-Function
SF-36
 
Rothwell, 1997 [37]
42
Multiple sclerosis
EDSS
OPCS
SF-36
 
Sharrack, 1999 [42]
50
Multiple sclerosis
EDSS SNRS
Barthel Index FIM CAMBS dis. AI
SF-36 EuroQol VAS
 
Schwartz, 1999 [41]
274
Multiple sclerosis
SI
Disease steps AI
HSQ
 
Miller, 2000 [34]
300
Multiple sclerosis
EDSS MSFC
SIP physical
SIP psychosocial SF-36
 
Hobart, 2000 [26]
64
Multiple sclerosis
EDSS
Barthel Index FIM
SF-36 Well-being GHQ
 
Rasova, 2005 [36]
112
Multiple sclerosis
Muscle performance Pulmonary ventilation
Barthel Index
 
MSQL
Rubenstein, 1998 [38]
193
Parkinson's disease
HY UPDRS motor
FSQ (BADL, IADL)
SF-36
 
Schrag, 2000 [40]
79
Parkinson's Disease
H&Y UPDRS motor
PDQ-39 ADL
EuroQol VAS SF-36
PDQ-39
Franchignoni, 2005 [23]
70
Parkinson's Disease
BBS PCS
UPDRS-ADL
 
PDQ-39
de Haan, 1993 [21]
81
Stroke
Mathew Orgogozo SSS NIHSS CNS
Barthel Index
SIP
 
Gottlieb, 2001 [25]
100
Stroke
Clas. Reding
FIM
LSI-a
 
Fuhrer, 1992 [24]
140
Spinal Cord Injury
ASIA
FIM
LSI-a
 
May, 2002 [33]
98
Spinal Cord Injury
ASIA
FIM
 
QLI
Marx, 2001 [32]
42
Knee disorders
AAOS Lysholm scale
KOS-ADL
SF-36
 
Paxton, 2003 [35]
110
Patellar dislocation
Fulkerson Kujala IKDC Lysholm
Tegner
 
MFA
MacDermid, 2001 [31]
70
Elbow pathology
ASES pain PREE pain
DASH
SF-36
 
Beaton, 1996 [18]
90
Shoulder disorder
Elevation of the shoulder
SST pASES
SF-36 (acute version)
 
Lindeboom, 1998 [30]
64
Cervical dystonia
Tsui TWSTRS-P
TWSTRS-D
SF-20
 
Vinik, 2005 [44]
262
Diabetic neuropathy
TNS
QOL-DN ADL
 
QOL-DN
Kahn, 2001 [28]
86
Facial nerve paralysis
FaCE
FDI – physical functioning
 
FDI – social-well being
Cleary, 1993 [20]
189
AIDS
Extreme pain Total symptom score
FSQ (BADL, IADL)
ORLS Mental Health
 
Speyer, 2004 [43]
77
Chronic dysphonia
Voice disorder severity
Impairment daily living
 
VHI
Hu, 2005 [27]
58
COPD
Breathlessness (VAS)
BDI PSFDQ-Act
SF-36
 
Zachariae, 2002 [46]
6497
Psoriasis
PASI Severity
PDI
 
PLSI
Abbreviations (in alphabetic order):
AAOS: American Academy of Orthopaedic Surgeons sports knee-rating scale. AI: Ambulation Index. AIMS2: Arthritis Impact Measurement Scales revised. ARA: American Rheumatism Association's functional classes. ASIA: Total Motor Index Score. (p)cASES: (patient) clinical American Shoulder and Elbow Surgeons questionnaire. BBS: Berg Balance Scale. BDI: Baseline Dyspnea Index. CAMBS: Cambridge Multiple Sclerosis Basic Score. CNS: Canadian Neurological Scale. COPD: Chronic Obstructive Pulmonary Disease. DASH: Disability of the Arm, Shoulder and Hand questionnaire. EDSS: Kurtzke Expanded Disability Scale. FaCE: Facial Clinimetric Evaluation. FDI: Facial Disability Index. FIM: Functional Independence Measure. FSQ: Functional Status Questionnaire (BADL: basic activities of daily life, IADL: instrumental activities of daily life). GHQ: General Health Questionnaire. Global GI severity: global gastrointestinal severity. HAQ: Stanford Health Assessment Questionnaire functional disability index. HSQ: Health Status Questionnaire. H&Y: Hoehn and Yahr. IKDC: International Knee Documentation Committee form. KOS: Knee Outcome Scale. LSIa: Life Satisfaction Index, version A. MFA: Musculoskeletal Function Assessment. MHAQ: Modified Health Assessment Questionnaire. MSFC: Multiple Sclerosis Functional Composite. MSQL: Multiple Sclerosis Quality of life scale. NIHSS: National Institutes of Health Stroke Scale. OPCS: Office of Population Census and Survey disability scale. ORLS: Overall Rating of Life Satisfaction. OSRA: Overall Status measure for Rheumatoid Arthritis. PASI: Psoriasis Area and Severity Index. PCS: Postural Changes Scale. PDI: Psoriasis Disability Index. PDQ-39: Parkinson Disease Questionnaire. PFSDQ-Act: Pulmonary Functional Status and Dyspnea Questionnaire. PLSI: Psoriasis Life Stress Inventory. PREE: Patient-rated Elbow Evaluation. QLI: Ferrans and Powers Quality of life Index. QOL-DN: Norfolk Quality of life Questionnaire-Diabetic Neuropathy. SF-20: Medical Outcome Study 20-Item Short-Form Health Survey. SF-36: Medical Outcome Study 36-Item. SI: Symptom Inventory. SNRS: Scripps Neurological Rating Scale. SSS: Scandinavian Stroke Scale. SST: Simple Shoulder Test. TNS: Total Neuropathy Score. TWSTRS-P(D): Toronto Western Spasmodic Torticollis Rating Scale-Pain(Disability). UPDRS: Unified Parkinson' Disease Rating Scale. VHI: Voice Handicap Index. WOMAC; Western Ontario and McMaster Universities.
The studies included a wide range of disease-related impairment measures, as well as a variety of disability measures (Table 1), in which the Functional Independence Measure (FIM) was the most often used. With regard to the HRQL measures, 17 studies used the SF-36 (or SF-20), 12 studies reported both the physical component and mental component scores, in two studies [37, 42] the mental health dimension was considered as mental HRQL. Other scales that were considered as a mental component of HRQL were the psychosocial dimension of the Sickness Impact Profile (SIP) [21, 22, 34], psychological well-being and the General Health Questionnaire (GHQ) [26], the mental dimension of the Multiple Sclerosis HRQL scale (MSQL) [36], the social well-being dimension of the Facial Disability Index (FDI) [28], the Overall Rating of Life satisfaction (ORLS) [20], and the emotional subscale of the Voice Handicap Index (VHI) [43].
Overall the studies included 86 correlations between impairment and disability and 104 correlations between impairment and HRQL. Five studies reported only one single correlation [24, 25, 28, 33, 44], for the remaining studies mean ES(z) were calculated for each health domain. Table 2 presents effect sizes of the 31 studies included. Thirteen studies (42%) reported large ES(z) between impairment and disability (≥ 0.81), whereas 81% of the ES(z) related to HRQL was small to moderate (≤ 0.50). The ES(z) between impairment and the different types of HRQL were on average small to moderate, except for disease-specific HRQL; 50% of the studies reported moderate to large ES(z) (0.51 – 0.80).
Table 2
ES(z) of the studies included in the meta-analysis
 
ES(z) impairment – disability (n = 31)
ES(z) impairment – HRQL (n = 31)
References
 
generic (n = 23)
disease-specific (n = 10)
physical (n = 13)
mental (n = 21)
Deyo, 1983 [22]
0.23
0.31
  
0.32
Birrell, 1998 [19]
0.81
0.49
 
0.65
0.37
Kvien, 1998 [29]
0.50
0.39
0.42
 
0.41
Wolfe, 2000 [45]
0.35
0.38
 
0.47
0.29
Angst, 2004 [16]
0.60
0.07
 
0.29
-0.15
Angst, 2005 [17]
0.60
0.11
 
0.41
-0.17
Salaffi, 2005 [39]
1.00
0.46
 
0.41
0.51
Rothwell, 1997 [37]
1.30
0.15
  
0.05
Sharrack, 1999 [42]
1.05
0.48
  
0.21
Schwartz, 1999 [41]
0.50
0.68
   
Miller, 2000 [34]
1.02
0.18
 
0.18
0.18
Hobart, 2000 [26]
1.33
0.06
 
0.34
0.14
Rasova, 2005 [36]
0.56
 
0.22
0.39
0.04
Rubenstein, 1998 [38]
0.73
0.40
 
0.48
0.31
Schrag, 2000 [40]
0.66
0.32
0.55
0.49
0.21
Franchignoni, 2005 [23]
0.79
 
0.71
  
de Haan, 1993 [21]
0.87
0.52
  
0.37
Gottlieb, 2001 [25]
0.55
0.16
   
Fuhrer, 1992 [24]
0.85
0.04
   
May, 2002 [33]
1.26
 
0.06
  
Marx, 2001 [32]
1.19
0.35
 
0.83
0.01
Paxton, 2003 [35]
0.35
 
0.49
  
MacDermid, 2001 [31]
0.85
0.41
 
0.54
0.29
Beaton, 1996 [18]
0.40
0.28
   
Lindeboom, 1998 [30]
0.23
0.21
   
Vinik, 2005 [44]
0.66
 
0.59
  
Kahn, 2001 [28]
0.87
 
0.78
 
0.78
Cleary, 1993 [20]
0.60
0.38
  
0.38
Speyer, 2004 [43]
1.05
 
0.55
 
0.44
Hu, 2005 [27]
0.46
0.45
 
0.29
0.60
Zachariae, 2002 [46]
0.44
 
0.40
  

Data synthesis

Review of the normal quantile plots (Figure 2 and 3) showed that one study [46] substantially deviated from normality. Removal of this study revealed statistical homogeneity of the datasets for the association between impairment and disability (Q statistics, p = 0.34), and between impairment and HRQL (Q statistics, p = 0.15).
On aggregate level (Figure 4), there was a moderate to large association between impairment and disability (pooled ES(z) = 0.69; 95% CI, 0.66 – 0.72). The aggregated relationship between impairment and HRQL was statistically significant smaller (pooled ES(z) = 0.38; 95% CI, 0.36 – 0.41). Backward transformation in correlation coefficients resulted in a moderate association between impairment and disability (r = 0.60; r2 = 36%) and a weak association between impairment and HRQL (r = 0.36; r2 = 13%).

Subgroup analyses

Table 2 presents the ES(z) per study used for the subgroup analyses. Figure 4 also depicts the various impairment – HRQL subgroup analyses. No statistical heterogeneity could be demonstrated (range p-values of the Q statistics 0.35 – 0.44), with the exception of the association between impairment and the mental component of HRQL (p = 0.06).
The pooled ES(z) between impairment and generic HRQL measures was 0.36 (95% CI, 0.33 – 0.39; r = 0.35; r2 = 12%) [1622, 2427, 2932, 34, 3742, 45]. The pooled ES(z) between impairment and disease-specific HRQL measures was significantly higher (pooled ES(z) = 0.46; 95% CI, 0.40 – 0.51; r = 0.43; r2 = 18%) [23, 28, 29, 33, 35, 36, 40, 43, 44, 46]. Impairment measures were significantly higher related with the physical component of the HRQL measures (pooled ES(z) = 0.43; 95% CI, 0.39 – 0.47; r = 0.41; r2 = 17%) [16, 17, 19, 26, 27, 31, 32, 34, 36, 3840, 45] than with the mental component (pooled ES(z) = 0.28; 95% CI, 0.20 – 0.36 [random effects model]; r = 0.27; r2 = 7%) [16, 17, 1922, 2629, 31, 32, 34, 3640, 42, 43, 45].

Publication bias

Review of normal quantile plots showed no clear indications for publication bias in both the analyses for the relationship impairment and disability and for impairment and HRQL (Figure 2 and 3). In addition, publication bias was not evident when the Spearman's rho rank correlation method was used (both p > 0.50). The fail-safe calculation by Rosenthal's method retrieved for both analyses a large number of studies (n = 27077/n = 9755) needed to be added in order to change the results of the meta-analysis.

Discussion

In this study we investigated the impact of impairments on patients' functional health in a spectrum of diseases. The results of the meta-analysis show that impairments explain 36% of the variance of the disability scores and 13% of the variance of HRQL scores. Impairment scales account for 17% of the physical dimension of HRQL, but can explain no more than 7% of the psychological aspects of HRQL [47].
Due to the great variability in disease-related impairment scales and disability and HRQL instruments used in patient groups with a wide range of disorders, we expected heterogeneous data sets. Interestingly, after removal of one study which deviated from normality, homogeneity could be demonstrated in all analyses, except when we investigated the relationship between impairment and the mental component of HRQL. Possibly, this type of HRQL is less clearly defined compared to the other types of functional outcomes.
Treatments, such as new drugs or new surgical or radiological interventions, are aimed at reducing mortality and morbidity. If these treatments reduce impairments, the beneficial effects on functional health will be far more better detectable in the patient's level of disability than in his or her level of HRQL. Moreover, if the outcome is assessed in terms of HRQL, treatment effects will be more visible in the physical component than in the mental components, and will be better reflected in the disease-specific measures than in the generic HRQL measures. Therefore, outcome measures at the level of functioning of patients should be selected carefully when clinical studies are designed. It clearly does matter on which level the functional outcome measurement is chosen.
No doubt, HRQL scales represent an important measure from a patient's point of view, but have serious disadvantages in many clinical efficacy studies. The extent to which patients fulfill social roles and participate in their environment cannot be observed directly and depends not only on their functional ability, but also on personal traits, social circumstances and societal barriers. In particular, HRQL scores, which reflect the patient's perception of the consequences of disease, depend on numerous additional, usually psychosocial, factors other than the disease itself. This explains why the correlation between impairments and HRQL scores is weak, especially when emphasis is laid on subjective psychological scores of these scales. The subjective HRQL scores therefore are often beyond the influence of the physician. In the primary assessment of new drugs or new surgical procedures, there are many outcomes of interest and precisely defining them and measuring them will improve assessing the impact of new interventions. In contrast, disability (mobility, self-care) seem to be a more appropriate primary end point for assessing the functional health status of patients. The ability to perform basic and complex activities of daily life is, as we showed, not only better related to the disease process itself, but is also observable and predictive of dependence [48], and forms an essential aspect of the patient's HRQL [49], an aspect which is amenable for treatment.
A shortcoming of this meta-analysis might be that there are probably more studies than the 31 we found. Our search strategy was based on the ICIDH and ICF terms and few researchers distinguish between the terms impairment, disability and HRQL. If they distinguished between these terms correlations between impairment and disability or between impairment and HRQL were given rarely for all three domains together. Another point of discussion may be the concern for publication bias. However, the normal quantile plots, Spearman's rank correlation coefficient method and fail-safe calculation method do not give an indication for this type of bias. Finally and unfortunately, we were not able to perform subgroup analysis based on the methodological quality of the studies. This because the psychometric and clinimetric articles analyzed used a hotchpotch of research designs which made it impossible to formulate unequivocal methodological criteria in terms of, for example, appropriateness of the design chosen, sample size consideration, blind assessment of outcome parameters, statistical adjustment for confounders, or loss to follow-up [50].

Conclusion

New drugs or new surgical or radiological treatments are developed from a pathophysiologic perspective and are primarily directed at reducing impairments. Traditionally, biological and impairment measures are preferred. Increasingly, it becomes evident that this type of outcome is not always relevant for patients [21, 51]. Our study shows that patient's impairments are clearly better reflected in disability measures, than in HRQL instruments. The relatively low association between impairment and HRQL is found in patients with various disorders, therefore we conclude that to assess the efficacy of a new treatment, disability is an important functional endpoint in clinical studies.

Acknowledgements

We would like to thank Koos Zwinderman for his statistical advice.
N. Weisscher is supported by a grant from the Anton Meelmeijer Fonds, a charity supporting innovative research in the Academic Medical Center, Amsterdam, the Netherlands.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

NW, RdH and MV initiated the project. NW and RdH screened, extracted and analysed the data. All authors participated in the discussion of the results, in the writing of the paper, and read and approved the final manuscript.
Literatur
2.
Zurück zum Zitat World Health Organization: International Classification of Impairment, Disabilities, and Handicaps. Geneva. 1980 World Health Organization: International Classification of Impairment, Disabilities, and Handicaps. Geneva. 1980
3.
Zurück zum Zitat World Health Organization: International Classification of Functioning, Disability, and Health. Geneva, Switzerland. 2001 World Health Organization: International Classification of Functioning, Disability, and Health. Geneva, Switzerland. 2001
4.
Zurück zum Zitat de Haan R, Aaronson N, Limburg M, Hewer RL, van Crevel H: Measuring quality of life in stroke. Stroke. 1993, 24: 320-327.CrossRefPubMed de Haan R, Aaronson N, Limburg M, Hewer RL, van Crevel H: Measuring quality of life in stroke. Stroke. 1993, 24: 320-327.CrossRefPubMed
5.
Zurück zum Zitat Aaronson NK: Quality of life: what is it? How should it be measured?. Oncology (Williston Park). 1988, 2: 69-76, 64. Aaronson NK: Quality of life: what is it? How should it be measured?. Oncology (Williston Park). 1988, 2: 69-76, 64.
6.
Zurück zum Zitat Fitzpatrick R, Davey C, Buxton MJ, Jones DR: Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess. 1998, 2: i-74.PubMed Fitzpatrick R, Davey C, Buxton MJ, Jones DR: Evaluating patient-based outcome measures for use in clinical trials. Health Technol Assess. 1998, 2: i-74.PubMed
7.
Zurück zum Zitat Sackett DL, Torrance GW: The utility of different health states as perceived by the general public. J Chronic Dis. 1978, 31: 70-10.1016/0021-9681(78)90072-3.CrossRef Sackett DL, Torrance GW: The utility of different health states as perceived by the general public. J Chronic Dis. 1978, 31: 70-10.1016/0021-9681(78)90072-3.CrossRef
8.
Zurück zum Zitat Fisher R: Statistical Methods for Research Workers. 1925, Edinburgh: Oliver & Boyd Fisher R: Statistical Methods for Research Workers. 1925, Edinburgh: Oliver & Boyd
9.
Zurück zum Zitat Rosenthal R: Parametric Measures of Effect Size. The Handbook of Research Synthesis. Edited by: Cooper H, Hedges LV. 1994, New York: Russel Sage Foundation, 231-44. Rosenthal R: Parametric Measures of Effect Size. The Handbook of Research Synthesis. Edited by: Cooper H, Hedges LV. 1994, New York: Russel Sage Foundation, 231-44.
10.
Zurück zum Zitat Shadish W, Haddock C: Combining Estimates of Effect Size. The Handbook of Research Synthesis. Edited by: Cooper H, Hedges LV. 1994, New York: Russell Sage Foundation, 261-82. Shadish W, Haddock C: Combining Estimates of Effect Size. The Handbook of Research Synthesis. Edited by: Cooper H, Hedges LV. 1994, New York: Russell Sage Foundation, 261-82.
11.
Zurück zum Zitat Cohen J: Statisical power analysis for the behavioural science. 1977, New York: Academic Press Cohen J: Statisical power analysis for the behavioural science. 1977, New York: Academic Press
12.
Zurück zum Zitat Sokal R, Rohlf F: Biometry. 1995, San Francisco: Freeman, 3 Sokal R, Rohlf F: Biometry. 1995, San Francisco: Freeman, 3
13.
Zurück zum Zitat Swinscow TDV: Correlation and regression. Statistics at Square One. 1997, University of Southampton: BMJ Publishing Group, ninth Swinscow TDV: Correlation and regression. Statistics at Square One. 1997, University of Southampton: BMJ Publishing Group, ninth
14.
Zurück zum Zitat Wang MC, Bushman BJ: Using the Normal Quantile Plot to Explore Meta-Analytic Data Sets. Psychol Med. 1998, 3: 46-54. Wang MC, Bushman BJ: Using the Normal Quantile Plot to Explore Meta-Analytic Data Sets. Psychol Med. 1998, 3: 46-54.
15.
Zurück zum Zitat Rosenthal R: The "file drawer problem" and tolerance for null results. Psychol Bull. 1979, 86: 638-641. 10.1037/0033-2909.86.3.638.CrossRef Rosenthal R: The "file drawer problem" and tolerance for null results. Psychol Bull. 1979, 86: 638-641. 10.1037/0033-2909.86.3.638.CrossRef
16.
Zurück zum Zitat Angst F, Pap G, Mannion AF, Herren DB, Aeschlimann A, Schwyzer HK, Simmen BR: Comprehensive assessment of clinical outcome and quality of life after total shoulder arthroplasty: usefulness and validity of subjective outcome measures. Arthritis Rheum. 2004, 51: 819-828. 10.1002/art.20688.CrossRefPubMed Angst F, Pap G, Mannion AF, Herren DB, Aeschlimann A, Schwyzer HK, Simmen BR: Comprehensive assessment of clinical outcome and quality of life after total shoulder arthroplasty: usefulness and validity of subjective outcome measures. Arthritis Rheum. 2004, 51: 819-828. 10.1002/art.20688.CrossRefPubMed
17.
Zurück zum Zitat Angst F, John M, Pap G, Mannion AF, Herren DB, Flury M, Aeschlimann A, Schwyzer HK, Simmen BR: Comprehensive assessment of clinical outcome and quality of life after total elbow arthroplasty. Arthritis Rheum. 2005, 53: 73-82. 10.1002/art.20911.CrossRefPubMed Angst F, John M, Pap G, Mannion AF, Herren DB, Flury M, Aeschlimann A, Schwyzer HK, Simmen BR: Comprehensive assessment of clinical outcome and quality of life after total elbow arthroplasty. Arthritis Rheum. 2005, 53: 73-82. 10.1002/art.20911.CrossRefPubMed
18.
Zurück zum Zitat Beaton DE, Richards RR: Measuring Function of the Shoulder. A Cross-Sectional Comparison of Five Questionnaires. J Bone Joint Surg Am. 1996, 78: 882-890.PubMed Beaton DE, Richards RR: Measuring Function of the Shoulder. A Cross-Sectional Comparison of Five Questionnaires. J Bone Joint Surg Am. 1996, 78: 882-890.PubMed
19.
Zurück zum Zitat Birrell FN, Hassell AB, Jones PW, Dawes PT: Why not use OSRA? A comparison of Overall Status in Rheumatoid Arthritis (RA) with ACR core set and other indices of disease activity in RA. J Rheumatol. 1998, 25: 1709-1715.PubMed Birrell FN, Hassell AB, Jones PW, Dawes PT: Why not use OSRA? A comparison of Overall Status in Rheumatoid Arthritis (RA) with ACR core set and other indices of disease activity in RA. J Rheumatol. 1998, 25: 1709-1715.PubMed
20.
Zurück zum Zitat Cleary PD, Fowler FJ, Weissman J, Massagli MP, Wilson I, Seage GR, Gatsonis C, Epstein A: Health-related quality of life in persons with acquired immune deficiency syndrome. Med Care. 1993, 31: 569-580. 10.1097/00005650-199307000-00001.CrossRefPubMed Cleary PD, Fowler FJ, Weissman J, Massagli MP, Wilson I, Seage GR, Gatsonis C, Epstein A: Health-related quality of life in persons with acquired immune deficiency syndrome. Med Care. 1993, 31: 569-580. 10.1097/00005650-199307000-00001.CrossRefPubMed
21.
Zurück zum Zitat de Haan R, Horn J, Limburg M, van der Meulen J, Bossuyt P: A comparison of five stroke scales with measures of disability, handicap, and quality of life. Stroke. 1993, 24: 1178-1181.CrossRefPubMed de Haan R, Horn J, Limburg M, van der Meulen J, Bossuyt P: A comparison of five stroke scales with measures of disability, handicap, and quality of life. Stroke. 1993, 24: 1178-1181.CrossRefPubMed
22.
Zurück zum Zitat Deyo RA, Inui TS, Leininger JD, Overman SS: Measuring functional outcomes in chronic disease: a comparison of traditional scales and a self-administered health status questionnaire in patients with rheumatoid arthritis. Med Care. 1983, 21: 180-192. 10.1097/00005650-198302000-00006.CrossRefPubMed Deyo RA, Inui TS, Leininger JD, Overman SS: Measuring functional outcomes in chronic disease: a comparison of traditional scales and a self-administered health status questionnaire in patients with rheumatoid arthritis. Med Care. 1983, 21: 180-192. 10.1097/00005650-198302000-00006.CrossRefPubMed
23.
Zurück zum Zitat Franchignoni F, Martignoni E, Ferriero G, Pasetti C: Balance and fear of falling in Parkinson's disease. Parkinsonism Relat Disord. 2005, 11: 427-433. 10.1016/j.parkreldis.2005.05.005.CrossRefPubMed Franchignoni F, Martignoni E, Ferriero G, Pasetti C: Balance and fear of falling in Parkinson's disease. Parkinsonism Relat Disord. 2005, 11: 427-433. 10.1016/j.parkreldis.2005.05.005.CrossRefPubMed
24.
Zurück zum Zitat Fuhrer MJ, Rintala DH, Hart KA, Clearman R, Young ME: Relationship of life satisfaction to impairment, disability, and handicap among persons with spinal cord injury living in the community. Arch Phys Med Rehabil. 1992, 73: 552-557.PubMed Fuhrer MJ, Rintala DH, Hart KA, Clearman R, Young ME: Relationship of life satisfaction to impairment, disability, and handicap among persons with spinal cord injury living in the community. Arch Phys Med Rehabil. 1992, 73: 552-557.PubMed
25.
Zurück zum Zitat Gottlieb A, Golander H, Bar-Tal Y, Gottlieb D: The influence of social support and perceived control on handicap and quality of life after stroke. Aging (Milano). 2001, 13: 11-15. Gottlieb A, Golander H, Bar-Tal Y, Gottlieb D: The influence of social support and perceived control on handicap and quality of life after stroke. Aging (Milano). 2001, 13: 11-15.
26.
Zurück zum Zitat Hobart J, Freeman J, Thompson A: Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain. 2000, 123: 1027-1040. 10.1093/brain/123.5.1027.CrossRefPubMed Hobart J, Freeman J, Thompson A: Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain. 2000, 123: 1027-1040. 10.1093/brain/123.5.1027.CrossRefPubMed
27.
Zurück zum Zitat Hu J, Meek P: Health-related quality of life in individuals with chronic obstructive pulmonary disease. Heart Lung. 2005, 34: 415-422. 10.1016/j.hrtlng.2005.03.008.CrossRefPubMed Hu J, Meek P: Health-related quality of life in individuals with chronic obstructive pulmonary disease. Heart Lung. 2005, 34: 415-422. 10.1016/j.hrtlng.2005.03.008.CrossRefPubMed
28.
Zurück zum Zitat Kahn JB, Gliklich RE, Boyev KP, Stewart MG, Metson RB, McKenna MJ: Validation of a patient-graded instrument for facial nerve paralysis: The FaCE Scale. Laryngoscope. 2001, 111: 387-398. 10.1097/00005537-200103000-00005.CrossRefPubMed Kahn JB, Gliklich RE, Boyev KP, Stewart MG, Metson RB, McKenna MJ: Validation of a patient-graded instrument for facial nerve paralysis: The FaCE Scale. Laryngoscope. 2001, 111: 387-398. 10.1097/00005537-200103000-00005.CrossRefPubMed
29.
Zurück zum Zitat Kvien TK, Kaasa S, Smedstad LM: Performance of the Norwegian SF-36 Health Survey in Patients with Rheumatoid Arthritis. II. A Comparison of the SF-36 with Disease-Specific Measures. Journal of Clinical Epidemiology. 1998, 51: 1077-1086. 10.1016/S0895-4356(98)00099-7.CrossRefPubMed Kvien TK, Kaasa S, Smedstad LM: Performance of the Norwegian SF-36 Health Survey in Patients with Rheumatoid Arthritis. II. A Comparison of the SF-36 with Disease-Specific Measures. Journal of Clinical Epidemiology. 1998, 51: 1077-1086. 10.1016/S0895-4356(98)00099-7.CrossRefPubMed
30.
Zurück zum Zitat Lindeboom R, Brans JW, Aramideh M, Speelman HD, de Haan RJ: Treatment of cervical dystonia: a comparison of measures for outcome assessment. Mov Disord. 1998, 13: 706-712. 10.1002/mds.870130417.CrossRefPubMed Lindeboom R, Brans JW, Aramideh M, Speelman HD, de Haan RJ: Treatment of cervical dystonia: a comparison of measures for outcome assessment. Mov Disord. 1998, 13: 706-712. 10.1002/mds.870130417.CrossRefPubMed
31.
Zurück zum Zitat MacDermid JC: Outcome evaluation in patients with elbow pathology: issues in instrument development and evaluation. J Hand Ther. 2001, 14: 105-114.CrossRefPubMed MacDermid JC: Outcome evaluation in patients with elbow pathology: issues in instrument development and evaluation. J Hand Ther. 2001, 14: 105-114.CrossRefPubMed
32.
Zurück zum Zitat Marx RG, Jones EC, Allen AA, Altchek DW, O'Brien SJ, Rodeo SA, Williams RJ, Warren RF, Wickiewicz TL: Reliability, validity, and responsiveness of four knee outcome scales for athletic patients. J Bone Joint Surg Am. 2001, 83-A: 1459-1469.PubMed Marx RG, Jones EC, Allen AA, Altchek DW, O'Brien SJ, Rodeo SA, Williams RJ, Warren RF, Wickiewicz TL: Reliability, validity, and responsiveness of four knee outcome scales for athletic patients. J Bone Joint Surg Am. 2001, 83-A: 1459-1469.PubMed
33.
Zurück zum Zitat May LA, Warren S: Measuring quality of life of persons with spinal cord injury: external and structural validity. Spinal Cord. 2002, 40: 341-350. 10.1038/sj.sc.3101311.CrossRefPubMed May LA, Warren S: Measuring quality of life of persons with spinal cord injury: external and structural validity. Spinal Cord. 2002, 40: 341-350. 10.1038/sj.sc.3101311.CrossRefPubMed
34.
Zurück zum Zitat Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS: Clinical Significance of the Multiple Sclerosis Functional Composite: Relationship to Patient-Reported Quality of Life. Arch Neurol. 2000, 57: 1319-1324. 10.1001/archneur.57.9.1319.PubMed Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS: Clinical Significance of the Multiple Sclerosis Functional Composite: Relationship to Patient-Reported Quality of Life. Arch Neurol. 2000, 57: 1319-1324. 10.1001/archneur.57.9.1319.PubMed
35.
Zurück zum Zitat Paxton EW, Fithian DC, Stone ML, Silva P: The Reliability and Validity of Knee-Specific and General Health Instruments in Assessing Acute Patellar Dislocation Outcomes. Am J Sports Med. 2003, 31: 487-492.PubMed Paxton EW, Fithian DC, Stone ML, Silva P: The Reliability and Validity of Knee-Specific and General Health Instruments in Assessing Acute Patellar Dislocation Outcomes. Am J Sports Med. 2003, 31: 487-492.PubMed
36.
Zurück zum Zitat Rasova K, Brandejsky P, Havrdova E, Zalisova M, Rexova P: Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis?. Mult Scler. 2005, 11: 213-221. 10.1191/1352458505ms1155oa.CrossRefPubMed Rasova K, Brandejsky P, Havrdova E, Zalisova M, Rexova P: Spiroergometric and spirometric parameters in patients with multiple sclerosis: are there any links between these parameters and fatigue, depression, neurological impairment, disability, handicap and quality of life in multiple sclerosis?. Mult Scler. 2005, 11: 213-221. 10.1191/1352458505ms1155oa.CrossRefPubMed
37.
Zurück zum Zitat Rothwell PM, McDowell Z, Wong CK, Dorman PJ: Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ. 1997, 314: 1580-CrossRefPubMedPubMedCentral Rothwell PM, McDowell Z, Wong CK, Dorman PJ: Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis. BMJ. 1997, 314: 1580-CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Rubenstein LM, Voelker MD, Chrischilles EA, Glenn DC, Wallace RB, Rodnitzky RL: The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson's disease research. Qual Life Res. 1998, 7: 279-290. 10.1023/A:1008838317063.CrossRefPubMed Rubenstein LM, Voelker MD, Chrischilles EA, Glenn DC, Wallace RB, Rodnitzky RL: The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson's disease research. Qual Life Res. 1998, 7: 279-290. 10.1023/A:1008838317063.CrossRefPubMed
39.
Zurück zum Zitat Salaffi F, Carotti M, Grassi W: Health-related quality of life in patients with hip or knee osteoarthritis: comparison of generic and disease-specific instruments. Clinical Rheumatology. 2005, 24: 29-37. 10.1007/s10067-004-0965-9.CrossRefPubMed Salaffi F, Carotti M, Grassi W: Health-related quality of life in patients with hip or knee osteoarthritis: comparison of generic and disease-specific instruments. Clinical Rheumatology. 2005, 24: 29-37. 10.1007/s10067-004-0965-9.CrossRefPubMed
40.
Zurück zum Zitat Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D – a generic quality of life measure – is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000, 69: 67-73. 10.1136/jnnp.69.1.67.CrossRefPubMedPubMedCentral Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D – a generic quality of life measure – is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000, 69: 67-73. 10.1136/jnnp.69.1.67.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Schwartz CE, Vollmer T, Lee H: Reliability and validity of two self-report measures of impairment and disability for MS. Neurology. 1999, 52: 63-CrossRefPubMed Schwartz CE, Vollmer T, Lee H: Reliability and validity of two self-report measures of impairment and disability for MS. Neurology. 1999, 52: 63-CrossRefPubMed
42.
Zurück zum Zitat Sharrack B, Hughes RAC, Soudain S, Dunn G: The psychometric properties of clinical rating scales used in multiple sclerosis. Brain. 1999, 122: 141-159. 10.1093/brain/122.1.141.CrossRefPubMed Sharrack B, Hughes RAC, Soudain S, Dunn G: The psychometric properties of clinical rating scales used in multiple sclerosis. Brain. 1999, 122: 141-159. 10.1093/brain/122.1.141.CrossRefPubMed
43.
Zurück zum Zitat Speyer R, Wieneke GH, Dejonckere PH: Self-assessment of voice therapy for chronic dysphonia. Clinical Otolaryngology and Allied Sciences. 2004, 29: 66-74. 10.1111/j.1365-2273.2004.00782.x.CrossRefPubMed Speyer R, Wieneke GH, Dejonckere PH: Self-assessment of voice therapy for chronic dysphonia. Clinical Otolaryngology and Allied Sciences. 2004, 29: 66-74. 10.1111/j.1365-2273.2004.00782.x.CrossRefPubMed
44.
Zurück zum Zitat Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI: The Development and Validation of the Norfolk QOL-DN, a New Measure of Patients' Perception of the Effects of Diabetes and Diabetic Neuropathy. Diabetes Technology & Therapeutics. 2005, 7: 497-508. 10.1089/dia.2005.7.497.CrossRef Vinik EJ, Hayes RP, Oglesby A, Bastyr E, Barlow P, Ford-Molvik SL, Vinik AI: The Development and Validation of the Norfolk QOL-DN, a New Measure of Patients' Perception of the Effects of Diabetes and Diabetic Neuropathy. Diabetes Technology & Therapeutics. 2005, 7: 497-508. 10.1089/dia.2005.7.497.CrossRef
45.
Zurück zum Zitat Wolfe F, Kong SX, Watson DJ: Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol. 2000, 27: 1373-1378.PubMed Wolfe F, Kong SX, Watson DJ: Gastrointestinal symptoms and health related quality of life in patients with arthritis. J Rheumatol. 2000, 27: 1373-1378.PubMed
46.
Zurück zum Zitat Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B: Quality of life in 6497 Nordic patients with psoriasis. British Journal of Dermatology. 2002, 146: 1006-1016. 10.1046/j.1365-2133.2002.04742.x.CrossRefPubMed Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B: Quality of life in 6497 Nordic patients with psoriasis. British Journal of Dermatology. 2002, 146: 1006-1016. 10.1046/j.1365-2133.2002.04742.x.CrossRefPubMed
47.
Zurück zum Zitat Abrahamson JH, Abrahamson ZH: Measures of strength. Abrahamson JH, Abrahamson ZH. Making sense of data. A self-instruction manual on the interpretation of epidemiologic data. 2001, Oxford: Oxford University Press, 234-238. 3CrossRef Abrahamson JH, Abrahamson ZH: Measures of strength. Abrahamson JH, Abrahamson ZH. Making sense of data. A self-instruction manual on the interpretation of epidemiologic data. 2001, Oxford: Oxford University Press, 234-238. 3CrossRef
48.
49.
Zurück zum Zitat Fries JF, Singh G: The hierarchy of patient outcomes. Quality of life and pharmacoeconomics in clinical trials. Edited by: Spilker B. 1996, Philadelphia: Lippincott-Raven Publishers, USA, 33-40. Fries JF, Singh G: The hierarchy of patient outcomes. Quality of life and pharmacoeconomics in clinical trials. Edited by: Spilker B. 1996, Philadelphia: Lippincott-Raven Publishers, USA, 33-40.
50.
Zurück zum Zitat Wortman PM: Judging Research Quality. The Handbook of Research Synthesis. Edited by: Cooper H, Hedges LV. 1994, New York: Russel Sage Foundation, 97-109. Wortman PM: Judging Research Quality. The Handbook of Research Synthesis. Edited by: Cooper H, Hedges LV. 1994, New York: Russel Sage Foundation, 97-109.
51.
Zurück zum Zitat Molenaar DS, Vermeulen M, de Visser M, de Haan R: Impact of neurologic signs and symptoms on functional status in peripheral neuropathies. Neurology. 1999, 52: 151-156.CrossRefPubMed Molenaar DS, Vermeulen M, de Visser M, de Haan R: Impact of neurologic signs and symptoms on functional status in peripheral neuropathies. Neurology. 1999, 52: 151-156.CrossRefPubMed
Metadaten
Titel
The impact of disease-related impairments on disability and health-related quality of life: a systematic review
verfasst von
Nadine Weisscher
Rob J de Haan
Marinus Vermeulen
Publikationsdatum
01.12.2007
Verlag
BioMed Central
Erschienen in
BMC Medical Research Methodology / Ausgabe 1/2007
Elektronische ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-7-24

Weitere Artikel der Ausgabe 1/2007

BMC Medical Research Methodology 1/2007 Zur Ausgabe